At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

Dr Anne-Claire Fougerousse is Head of Dermatology at the Bégin Hospital in Saint-Mandé, France, and scientific coordinator of a French network of dermatologists and allergists (ResoEczema). The focus of her work is to improve the care of adolescent and adult patients with atopic dermatitis (AD), a c...

Full description

Saved in:
Bibliographic Details
Published inDermatology and therapy Vol. 11; no. 2; pp. 331 - 338
Main Author Fougerousse, Anne-Claire
Format Journal Article
LanguageEnglish
Published Cheshire Springer Healthcare 01.04.2021
Springer
Subjects
Aims and objectives
Atopic dermatitis
Care and treatment
Commentary
Dermatology
Development and progression
Health care coalitions
Internal Medicine
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Oral and Maxillofacial Surgery
Planning
Plastic Surgery
Quality of Life Research
France
Dermatologist
Atopic dermatitis
Expert’s perspective
Online AccessGet full text

Cover

More Information
Summary:Dr Anne-Claire Fougerousse is Head of Dermatology at the Bégin Hospital in Saint-Mandé, France, and scientific coordinator of a French network of dermatologists and allergists (ResoEczema). The focus of her work is to improve the care of adolescent and adult patients with atopic dermatitis (AD), a chronic, pruritic inflammatory skin disease that substantially impacts patient quality of life. In this interview, Dr Fougerousse provides an overview of the clinical presentation of adult patients with AD and describes available treatments. Today, topical agents like emollients and corticosteroids are the mainstay of AD therapy, and patients with lesions that are resistant to optimally administered topical treatment can also receive phototherapy or systemic therapy with ciclosporin. Dr Fougerousse discusses her hopes for the future of AD therapy with the recent development of biologicals like dupilumab, which may provide improvements in clinical outcomes and quality of life for patients with moderate-to-severe AD. In the next few years, the therapeutic arsenal for AD will likely expand to include more systemic therapies providing sustained symptom control. The real challenge will be to ensure that the maximum number of patients with AD achieve clinical benefits from these new treatments.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:2193-8210
2190-9172
DOI:10.1007/s13555-021-00489-w